ALT - Altimmune Stock Is Rising Monday: What's Driving The Action? | Benzinga
Altimmune Inc (NASDAQ:ALT) shares are trading higher Monday after the company announced data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide.
What Happened: Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes Association’s 84th Scientific Sessions.
Pemvidutide is the clinical-stage biopharmaceutical company’s GLP-1/glucagon dual receptor agonist candidate.
The trial enrolled 391 subjects with obesity, or overweight with at least one co-morbidity and without diabetes. At week 48, subjects receiving pemvidutide achieved mean weight losses of 10.3%, 11.2%, 15.6% and 2.2% at the 1.2 mg, 1.8 mg, and 2.4 mg doses and placebo, respectively,
“We’re pleased ...